首页 > 最新文献

Hypertension最新文献

英文 中文
Brief Review and Primer of Key Terminology for Artificial Intelligence and Machine Learning in Hypertension. 高血压人工智能和机器学习关键术语简评与入门。
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-07-16 DOI: 10.1161/HYPERTENSIONAHA.123.22347
Patrick Dunn, Asif Ali, Akash P Patel, Srikanta Banerjee

Recent breakthroughs in artificial intelligence (AI) have caught the attention of many fields, including health care. The vision for AI is that a computer model can process information and provide output that is indistinguishable from that of a human and, in specific repetitive tasks, outperform a human's capability. The 2 critical underlying technologies in AI are used for supervised and unsupervised machine learning. Machine learning uses neural networks and deep learning modeled after the human brain from structured or unstructured data sets to learn, make decisions, and continuously improve the model. Natural language processing, used for supervised learning, is understanding, interpreting, and generating information using human language in chatbots and generative and conversational AI. These breakthroughs result from increased computing power and access to large data sets, setting the stage for releasing large language models, such as ChatGPT and others, and new imaging models using computer vision. Hypertension management involves using blood pressure and other biometric data from connected devices and generative AI to communicate with patients and health care professionals. AI can potentially improve hypertension diagnosis and treatment through remote patient monitoring and digital therapeutics.

人工智能(AI)最近取得的突破引起了包括医疗保健在内的许多领域的关注。人工智能的愿景是,计算机模型能够处理信息并提供与人类无异的输出结果,而且在特定的重复性任务中,能够超越人类的能力。人工智能的两项关键基础技术分别用于监督和非监督机器学习。机器学习使用仿照人脑的神经网络和深度学习,从结构化或非结构化数据集中学习、决策并不断改进模型。自然语言处理用于监督学习,是在聊天机器人、生成式人工智能和对话式人工智能中使用人类语言理解、解释和生成信息。这些突破源于计算能力的提高和对大型数据集的访问,为发布大型语言模型(如 ChatGPT 等)和使用计算机视觉的新成像模型创造了条件。高血压管理涉及使用来自联网设备的血压和其他生物识别数据以及生成式人工智能与患者和医疗保健专业人员进行交流。通过远程患者监测和数字疗法,人工智能有可能改善高血压的诊断和治疗。
{"title":"Brief Review and Primer of Key Terminology for Artificial Intelligence and Machine Learning in Hypertension.","authors":"Patrick Dunn, Asif Ali, Akash P Patel, Srikanta Banerjee","doi":"10.1161/HYPERTENSIONAHA.123.22347","DOIUrl":"10.1161/HYPERTENSIONAHA.123.22347","url":null,"abstract":"<p><p>Recent breakthroughs in artificial intelligence (AI) have caught the attention of many fields, including health care. The vision for AI is that a computer model can process information and provide output that is indistinguishable from that of a human and, in specific repetitive tasks, outperform a human's capability. The 2 critical underlying technologies in AI are used for supervised and unsupervised machine learning. Machine learning uses neural networks and deep learning modeled after the human brain from structured or unstructured data sets to learn, make decisions, and continuously improve the model. Natural language processing, used for supervised learning, is understanding, interpreting, and generating information using human language in chatbots and generative and conversational AI. These breakthroughs result from increased computing power and access to large data sets, setting the stage for releasing large language models, such as ChatGPT and others, and new imaging models using computer vision. Hypertension management involves using blood pressure and other biometric data from connected devices and generative AI to communicate with patients and health care professionals. AI can potentially improve hypertension diagnosis and treatment through remote patient monitoring and digital therapeutics.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"26-35"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming Hypertension Diagnosis and Management in The Era of Artificial Intelligence: A 2023 National Heart, Lung, and Blood Institute (NHLBI) Workshop Report. 人工智能时代的高血压诊断与管理变革:美国国家心肺血液研究所(NHLBI)2023 年研讨会报告。
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-07-16 DOI: 10.1161/HYPERTENSIONAHA.124.22095
Daichi Shimbo, Rashmee U Shah, Marwah Abdalla, Ritu Agarwal, Faraz S Ahmad, Gabriel Anaya, Zachi I Attia, Sheana Bull, Alexander R Chang, Yvonne Commodore-Mensah, Keith Ferdinand, Kensaku Kawamoto, Rohan Khera, Jane Leopold, James Luo, Sonya Makhni, Bobak J Mortazavi, Young S Oh, Lucia C Savage, Erica S Spatz, George Stergiou, Mintu P Turakhia, Paul K Whelton, Clyde W Yancy, Erin Iturriaga

Hypertension is among the most important risk factors for cardiovascular disease, chronic kidney disease, and dementia. The artificial intelligence (AI) field is advancing quickly, and there has been little discussion on how AI could be leveraged for improving the diagnosis and management of hypertension. AI technologies, including machine learning tools, could alter the way we diagnose and manage hypertension, with potential impacts for improving individual and population health. The development of successful AI tools in public health and health care systems requires diverse types of expertise with collaborative relationships between clinicians, engineers, and data scientists. Unbiased data sources, management, and analyses remain a foundational challenge. From a diagnostic standpoint, machine learning tools may improve the measurement of blood pressure and be useful in the prediction of incident hypertension. To advance the management of hypertension, machine learning tools may be useful to find personalized treatments for patients using analytics to predict response to antihypertension medications and the risk for hypertension-related complications. However, there are real-world implementation challenges to using AI tools in hypertension. Herein, we summarize key findings from a diverse group of stakeholders who participated in a workshop held by the National Heart, Lung, and Blood Institute in March 2023. Workshop participants presented information on communication gaps between clinical medicine, data science, and engineering in health care; novel approaches to estimating BP, hypertension risk, and BP control; and real-world implementation challenges and issues.

高血压是心血管疾病、慢性肾病和痴呆症最重要的风险因素之一。人工智能(AI)领域发展迅速,但关于如何利用人工智能改善高血压诊断和管理的讨论却很少。包括机器学习工具在内的人工智能技术可以改变我们诊断和管理高血压的方式,并对改善个人和群体健康产生潜在影响。在公共卫生和医疗保健系统中开发成功的人工智能工具需要不同类型的专业知识,以及临床医生、工程师和数据科学家之间的合作关系。公正的数据来源、管理和分析仍然是一项基本挑战。从诊断的角度来看,机器学习工具可以改进血压测量,并有助于预测高血压的发病率。为了推进高血压的管理,机器学习工具可能有助于通过分析预测患者对降压药物的反应和高血压相关并发症的风险,为患者找到个性化的治疗方法。然而,将人工智能工具用于高血压治疗在现实世界中还存在一些挑战。在此,我们总结了参加美国国家心肺血液研究所于 2023 年 3 月举办的研讨会的不同利益相关者的主要发现。研讨会与会者介绍了以下方面的信息:医疗保健中临床医学、数据科学和工程学之间的沟通差距;估测血压、高血压风险和血压控制的新方法;以及现实世界中的实施挑战和问题。
{"title":"Transforming Hypertension Diagnosis and Management in The Era of Artificial Intelligence: A 2023 National Heart, Lung, and Blood Institute (NHLBI) Workshop Report.","authors":"Daichi Shimbo, Rashmee U Shah, Marwah Abdalla, Ritu Agarwal, Faraz S Ahmad, Gabriel Anaya, Zachi I Attia, Sheana Bull, Alexander R Chang, Yvonne Commodore-Mensah, Keith Ferdinand, Kensaku Kawamoto, Rohan Khera, Jane Leopold, James Luo, Sonya Makhni, Bobak J Mortazavi, Young S Oh, Lucia C Savage, Erica S Spatz, George Stergiou, Mintu P Turakhia, Paul K Whelton, Clyde W Yancy, Erin Iturriaga","doi":"10.1161/HYPERTENSIONAHA.124.22095","DOIUrl":"10.1161/HYPERTENSIONAHA.124.22095","url":null,"abstract":"<p><p>Hypertension is among the most important risk factors for cardiovascular disease, chronic kidney disease, and dementia. The artificial intelligence (AI) field is advancing quickly, and there has been little discussion on how AI could be leveraged for improving the diagnosis and management of hypertension. AI technologies, including machine learning tools, could alter the way we diagnose and manage hypertension, with potential impacts for improving individual and population health. The development of successful AI tools in public health and health care systems requires diverse types of expertise with collaborative relationships between clinicians, engineers, and data scientists. Unbiased data sources, management, and analyses remain a foundational challenge. From a diagnostic standpoint, machine learning tools may improve the measurement of blood pressure and be useful in the prediction of incident hypertension. To advance the management of hypertension, machine learning tools may be useful to find personalized treatments for patients using analytics to predict response to antihypertension medications and the risk for hypertension-related complications. However, there are real-world implementation challenges to using AI tools in hypertension. Herein, we summarize key findings from a diverse group of stakeholders who participated in a workshop held by the National Heart, Lung, and Blood Institute in March 2023. Workshop participants presented information on communication gaps between clinical medicine, data science, and engineering in health care; novel approaches to estimating BP, hypertension risk, and BP control; and real-world implementation challenges and issues.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"36-45"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic Insights Into Redox Damage of the Podocyte in Hypertension. 高血压对荚膜细胞氧化还原损伤的机理认识
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-11-13 DOI: 10.1161/HYPERTENSIONAHA.124.22068
Daria V Ilatovskaya, Amanda Behr, Alexander Staruschenko, Gentzon Hall, Oleg Palygin

Podocytes are specialized cells within the glomerular filtration barrier, which are crucial for maintaining glomerular structural integrity and convective ultrafiltration. Podocytes exhibit a unique arborized morphology with foot processes interfacing by slit diaphragms, ladder-like, multimolecular sieves, which provide size and charge selectivity for ultrafiltration and transmembrane signaling. Podocyte dysfunction, resulting from oxidative stress, dysregulated prosurvival signaling, or structural damage, can drive the development of proteinuria and glomerulosclerosis in hypertensive nephropathy. Functionally, podocyte injury leads to actin cytoskeleton rearrangements, foot process effacement, dysregulated slit diaphragm protein expression, and impaired ultrafiltration. Notably, the renin-angiotensin system plays a pivotal role in podocyte function, with beneficial AT2R (angiotensin receptor 2)-mediated nitric oxide (NO) signaling to counteract AT1R (angiotensin receptor 1)-driven calcium (Ca2+) influx and oxidative stress. Disruption of this balance contributes significantly to podocyte dysfunction and drives albuminuria, a marker of kidney damage and overall disease progression. Oxidative stress can also lead to sustained ion channel-mediated Ca2+ influx and precipitate cytoskeletal disorganization. The complex interplay between GPCR (G-protein coupled receptor) signaling, ion channel activation, and redox injury pathways underscores the need for additional research aimed at identifying targeted therapies to protect podocytes and preserve glomerular function. Earlier detection of albuminuria and podocyte injury through routine noninvasive diagnostics will also be critical in populations at the highest risk for the development of hypertensive kidney disease. In this review, we highlight the established mechanisms of oxidative stress-mediated podocyte damage in proteinuric kidney diseases, with an emphasis on a hypertensive renal injury. We will also consider emerging therapies that have the potential to selectively protect podocytes from redox-related injury.

荚膜细胞是肾小球滤过屏障内的特化细胞,对维持肾小球结构完整性和对流超滤至关重要。荚膜细胞表现出独特的树枝状形态,其足突由狭缝隔膜、阶梯状多分子筛连接,为超滤和跨膜信号传导提供大小和电荷选择性。氧化应激、前存活信号失调或结构性损伤导致的荚膜细胞功能障碍,可促使高血压肾病患者出现蛋白尿和肾小球硬化。从功能上讲,荚膜细胞损伤会导致肌动蛋白细胞骨架重排、足突脱落、裂膈蛋白表达失调以及超滤功能受损。值得注意的是,肾素-血管紧张素系统在荚膜细胞功能中起着关键作用,血管紧张素受体 2(AT2R)介导的一氧化氮(NO)信号对抵消血管紧张素受体 1(AT1R)驱动的钙(Ca2+)流入和氧化应激有益。这种平衡的破坏在很大程度上导致荚膜细胞功能障碍,并引发白蛋白尿,而白蛋白尿是肾脏损伤和整体疾病进展的标志。氧化应激也会导致离子通道介导的 Ca2+ 持续流入,并引发细胞骨架紊乱。GPCR 信号传导、离子通道激活和氧化还原损伤途径之间复杂的相互作用突出表明,有必要开展更多研究,以确定保护荚膜细胞和维护肾小球功能的靶向疗法。在高血压肾病高危人群中,通过常规无创诊断及早发现白蛋白尿和荚膜损伤也至关重要。在本综述中,我们将重点介绍蛋白尿性肾病中氧化应激介导的荚膜细胞损伤的既定机制,重点是高血压肾损伤。我们还将探讨有可能选择性保护荚膜免受氧化还原相关损伤的新兴疗法。
{"title":"Mechanistic Insights Into Redox Damage of the Podocyte in Hypertension.","authors":"Daria V Ilatovskaya, Amanda Behr, Alexander Staruschenko, Gentzon Hall, Oleg Palygin","doi":"10.1161/HYPERTENSIONAHA.124.22068","DOIUrl":"10.1161/HYPERTENSIONAHA.124.22068","url":null,"abstract":"<p><p>Podocytes are specialized cells within the glomerular filtration barrier, which are crucial for maintaining glomerular structural integrity and convective ultrafiltration. Podocytes exhibit a unique arborized morphology with foot processes interfacing by slit diaphragms, ladder-like, multimolecular sieves, which provide size and charge selectivity for ultrafiltration and transmembrane signaling. Podocyte dysfunction, resulting from oxidative stress, dysregulated prosurvival signaling, or structural damage, can drive the development of proteinuria and glomerulosclerosis in hypertensive nephropathy. Functionally, podocyte injury leads to actin cytoskeleton rearrangements, foot process effacement, dysregulated slit diaphragm protein expression, and impaired ultrafiltration. Notably, the renin-angiotensin system plays a pivotal role in podocyte function, with beneficial AT2R (angiotensin receptor 2)-mediated nitric oxide (NO) signaling to counteract AT1R (angiotensin receptor 1)-driven calcium (Ca<sup>2+</sup>) influx and oxidative stress. Disruption of this balance contributes significantly to podocyte dysfunction and drives albuminuria, a marker of kidney damage and overall disease progression. Oxidative stress can also lead to sustained ion channel-mediated Ca<sup>2+</sup> influx and precipitate cytoskeletal disorganization. The complex interplay between GPCR (G-protein coupled receptor) signaling, ion channel activation, and redox injury pathways underscores the need for additional research aimed at identifying targeted therapies to protect podocytes and preserve glomerular function. Earlier detection of albuminuria and podocyte injury through routine noninvasive diagnostics will also be critical in populations at the highest risk for the development of hypertensive kidney disease. In this review, we highlight the established mechanisms of oxidative stress-mediated podocyte damage in proteinuric kidney diseases, with an emphasis on a hypertensive renal injury. We will also consider emerging therapies that have the potential to selectively protect podocytes from redox-related injury.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"14-25"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics of Hypertension: Additive and Interactive Effects. 高血压的遗传学:遗传学:高血压的叠加效应和交互效应
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-11-11 DOI: 10.1161/HYPERTENSIONAHA.124.21724
Zdenka Pausova, Johanne Tremblay, Pavel Hamet
{"title":"Genetics of Hypertension: Additive and Interactive Effects.","authors":"Zdenka Pausova, Johanne Tremblay, Pavel Hamet","doi":"10.1161/HYPERTENSIONAHA.124.21724","DOIUrl":"10.1161/HYPERTENSIONAHA.124.21724","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"3-7"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants. 血压对肾脏去神经化的反应与遗传变异无关
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1161/HYPERTENSIONAHA.124.23393
Christian Delles, Roland E Schmieder, Rónán Daly, Dennis Kannenkeril, Agnes Bosch, Lucas Lauder, Michael Kunz, Michael Böhm, Graham Hamilton, Raphael S Schmieder, Axel Schmid, Pawel Herzyk, Felix Mahfoud

Background: Renal denervation lowers blood pressure (BP) in patients with uncontrolled hypertension. We conducted an unbiased genomic screen to identify genetic variants that may associate with BP response to renal denervation (RDN).

Methods: Patients (n=268) with uncontrolled resistant hypertension (baseline BP, 166±21/90±15 mm Hg) who underwent endovascular RDN using the Symplicity catheter (Medtronic, Inc, Santa Rosa, CA) were included. Reduction in 24-hour ambulatory systolic BP was assessed at 6 months and divided into 2 groups: above and below the median response of 6.0 mm Hg, taking preintervention 24-hour ambulatory BP and regression to the mean into account. Whole exome sequencing assessing 249 669 variants, was conducted using Illumina NovaSeq technology read on a NovaSeq S4 Flow Cell device.

Results: We did not identify individual gene variants associated with BP response following RDN. These findings were confirmed after adjustment for sex and in a sensitivity analysis looking at tertiles of BP response. We also explored specific variants in AGT, ADD1, ADRB1, ADRB2, and SCNN1A that have been proposed as potential candidate genes for response and found no association (all P>0.13). Gene ontology analysis of variants across the 2 responder groups highlighted differences in biologic processes such as cell adhesion and molecular function such as protein tyrosine kinase activity.

Conclusions: The response to RDN, in terms of 24-hour BP reduction, was not associated with the genetic profile of patients with resistant hypertension. These data do not support the use of a genetic score to identify potential responders to RDN.

背景:肾脏去神经可降低未控制的高血压患者的血压(BP)。我们进行了一次无偏见的基因组筛选,以确定可能与肾脏去神经化(RDN)的血压反应有关的基因变异:方法:纳入使用 Symplicity 导管(美敦力公司,加利福尼亚州圣罗莎)接受血管内肾脏去神经治疗的未控制抵抗性高血压患者(n=268)(基线血压为 166±21/90±15 mm Hg)。在 6 个月时评估 24 小时动态收缩压的降低情况,并将其分为两组:高于和低于 6.0 mm Hg 的中位反应,同时考虑干预前的 24 小时动态收缩压和向平均值的回归。使用 Illumina NovaSeq 技术在 NovaSeq S4 Flow Cell 设备上进行全外显子组测序,评估了 249 669 个变异:我们没有发现与 RDN 后血压反应相关的单个基因变异。在对性别进行调整并对血压反应分层进行敏感性分析后,这些结果得到了证实。我们还研究了 AGT、ADD1、ADRB1、ADRB2 和 SCNN1A 中的特定变异,这些变异被认为是潜在的反应候选基因,但没有发现任何关联(P 均大于 0.13)。对两个反应组变异的基因本体分析强调了生物过程(如细胞粘附)和分子功能(如蛋白酪氨酸激酶活性)的差异:从 24 小时血压降低的角度来看,对 RDN 的反应与抵抗性高血压患者的遗传特征无关。这些数据并不支持使用基因评分来识别 RDN 的潜在应答者。
{"title":"Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants.","authors":"Christian Delles, Roland E Schmieder, Rónán Daly, Dennis Kannenkeril, Agnes Bosch, Lucas Lauder, Michael Kunz, Michael Böhm, Graham Hamilton, Raphael S Schmieder, Axel Schmid, Pawel Herzyk, Felix Mahfoud","doi":"10.1161/HYPERTENSIONAHA.124.23393","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23393","url":null,"abstract":"<p><strong>Background: </strong>Renal denervation lowers blood pressure (BP) in patients with uncontrolled hypertension. We conducted an unbiased genomic screen to identify genetic variants that may associate with BP response to renal denervation (RDN).</p><p><strong>Methods: </strong>Patients (n=268) with uncontrolled resistant hypertension (baseline BP, 166±21/90±15 mm Hg) who underwent endovascular RDN using the Symplicity catheter (Medtronic, Inc, Santa Rosa, CA) were included. Reduction in 24-hour ambulatory systolic BP was assessed at 6 months and divided into 2 groups: above and below the median response of 6.0 mm Hg, taking preintervention 24-hour ambulatory BP and regression to the mean into account. Whole exome sequencing assessing 249 669 variants, was conducted using Illumina NovaSeq technology read on a NovaSeq S4 Flow Cell device.</p><p><strong>Results: </strong>We did not identify individual gene variants associated with BP response following RDN. These findings were confirmed after adjustment for sex and in a sensitivity analysis looking at tertiles of BP response. We also explored specific variants in <i>AGT</i>, <i>ADD1</i>, ADRB1, <i>ADRB2</i>, and <i>SCNN1A</i> that have been proposed as potential candidate genes for response and found no association (all <i>P</i>>0.13). Gene ontology analysis of variants across the 2 responder groups highlighted differences in biologic processes such as cell adhesion and molecular function such as protein tyrosine kinase activity.</p><p><strong>Conclusions: </strong>The response to RDN, in terms of 24-hour BP reduction, was not associated with the genetic profile of patients with resistant hypertension. These data do not support the use of a genetic score to identify potential responders to RDN.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"118-125"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolutionary Characteristics in Primary Aldosteronism Patients. 原发性醛固酮增多症患者的演变特征
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-11-06 DOI: 10.1161/HYPERTENSIONAHA.124.23398
Yinjie Gao, Yu Wang, Yue Zhou, Xiaoyan Chang, Yushi Zhang, Min Nie, Anli Tong

Background: Primary aldosteronism is predominantly caused by excessive aldosterone production from the adrenal cortex, and the aldosterone-producing structures could take many forms, like adenomas, nodules, micronodules, and so on. Most studies of primary aldosteronism were limited to the hotspot driver genes responsible for autonomous aldosterone production; however, the panoramic genetic architecture and genomic alterations of aldosterone-producing structures and their adjacent hyperplasia glands remain unknown.

Methods: In this study, whole-exome sequencing and transcriptome sequencing (RNA-seq) analyses were performed using functional nodules and matched hyperplasia tissues, which were microdissected guided by aldosterone synthase immunohistochemistry. Phylogenetic trees were constructed based on the shared and unique mutations, gene mutation spectrums, and clonal characteristics.

Results: The rates of mutations represented higher means of functional nodules than hyperplasia samples, and the little mutational overlap was shown between the 2 groups on phylogenetic trees. The mutations of the aldosterone driver gene (KCNJ5 or CACNA1D) were only observed in functional nodules and indicated almost the largest values of cancer cell fraction. Moreover, the functional nodules also harbored some potential variants related to cell proliferation, which were not detected in hyperplasia tissues. Transcriptome analysis suggested that only 25.5% upregulated and 23.3% downregulated genes overlapped between functional nodules and hyperplasia tissues.

Conclusions: This study demonstrated a genetic and transcriptome landscape of aldosterone-producing structures and adjacent hyperplasia glands in primary aldosteronism. The results indicated independent clonal origins on functional nodules and hyperplasia tissues, and little mutual evolutionary relationship was found on their phylogenetic trees.

背景:原发性醛固酮增多症主要由肾上腺皮质分泌过多醛固酮引起,醛固酮分泌结构有多种形式,如腺瘤、结节、小结节等。大多数原发性醛固酮增多症的研究仅限于负责自主醛固酮生成的热点驱动基因,然而,醛固酮生成结构及其邻近增生腺体的全景遗传结构和基因组改变仍不为人知:本研究使用功能性结节和匹配的增生组织(在醛固酮合成酶免疫组化的指导下进行显微解剖)进行了全外显子组测序和转录组测序(RNA-seq)分析。根据共有突变和独特突变、基因突变谱和克隆特征构建了系统发生树:结果:功能性结节样本的突变率高于增生样本,两组样本在系统发生树上的突变重叠较少。醛固酮驱动基因(KCNJ5 或 CACNA1D)的突变仅在功能性结节中观察到,并显示出几乎最大的癌细胞比例值。此外,功能性结节中还存在一些与细胞增殖有关的潜在变异,而增生组织中没有检测到这些变异。转录组分析表明,功能性结节和增生组织之间只有 25.5%的上调基因和 23.3%的下调基因重叠:本研究显示了原发性醛固酮增多症患者醛固酮分泌结构和邻近增生腺体的基因和转录组情况。结果表明,功能性结节和增生组织具有独立的克隆起源,在它们的系统发生树上几乎没有发现相互的进化关系。
{"title":"Evolutionary Characteristics in Primary Aldosteronism Patients.","authors":"Yinjie Gao, Yu Wang, Yue Zhou, Xiaoyan Chang, Yushi Zhang, Min Nie, Anli Tong","doi":"10.1161/HYPERTENSIONAHA.124.23398","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23398","url":null,"abstract":"<p><strong>Background: </strong>Primary aldosteronism is predominantly caused by excessive aldosterone production from the adrenal cortex, and the aldosterone-producing structures could take many forms, like adenomas, nodules, micronodules, and so on. Most studies of primary aldosteronism were limited to the hotspot driver genes responsible for autonomous aldosterone production; however, the panoramic genetic architecture and genomic alterations of aldosterone-producing structures and their adjacent hyperplasia glands remain unknown.</p><p><strong>Methods: </strong>In this study, whole-exome sequencing and transcriptome sequencing (RNA-seq) analyses were performed using functional nodules and matched hyperplasia tissues, which were microdissected guided by aldosterone synthase immunohistochemistry. Phylogenetic trees were constructed based on the shared and unique mutations, gene mutation spectrums, and clonal characteristics.</p><p><strong>Results: </strong>The rates of mutations represented higher means of functional nodules than hyperplasia samples, and the little mutational overlap was shown between the 2 groups on phylogenetic trees. The mutations of the aldosterone driver gene (<i>KCNJ5</i> or <i>CACNA1D</i>) were only observed in functional nodules and indicated almost the largest values of cancer cell fraction. Moreover, the functional nodules also harbored some potential variants related to cell proliferation, which were not detected in hyperplasia tissues. Transcriptome analysis suggested that only 25.5% upregulated and 23.3% downregulated genes overlapped between functional nodules and hyperplasia tissues.</p><p><strong>Conclusions: </strong>This study demonstrated a genetic and transcriptome landscape of aldosterone-producing structures and adjacent hyperplasia glands in primary aldosteronism. The results indicated independent clonal origins on functional nodules and hyperplasia tissues, and little mutual evolutionary relationship was found on their phylogenetic trees.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"96-105"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Home Blood Pressure Measurements Are Not Performed According to Guidelines and Standardized Education Is Urgently Needed. 家庭血压测量未按指南进行,急需标准化教育。
IF 6.9 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1161/HYPERTENSIONAHA.124.23678
Eleanor Clapham, Dean S Picone, Samuel Carmichael, George S Stergiou, Norm R C Campbell, John Stevens, Carol Batt, Aletta E Schutte, Niamh Chapman

Background: Patient education is needed to perform home blood pressure measurement (HBPM) according to blood pressure (BP) guidelines. It is not known how BP is measured at home and what education is provided, which was the aim of the study.

Methods: Mixed-methods study among Australian adults who perform HBPM (June to December 2023). Participants completed a 30-item online survey on whether they followed guideline recommendations and the education they received for HBPM. Phone interviews were conducted among a purposive sample to further explore survey topics.

Results: Participants (n=350) were middle-aged (58±16 years; 54% women), and most (n=250, 71%) had hypertension. Guideline recommendations for HBPM were not always followed by survey participants. Most participants measured BP seated (n=316, 90%) with the cuff fitted to a bare arm (n=269, 77%). Only 15% measured BP in the morning and evening (n=54) and 26% averaged the BP readings over 7 days (n=90). Interview participants (n=34) described measuring BP at "different times of the day after doing different things." One-third of participants (n=112, 37%) received education for HBPM, which interview participants described as vague verbal instructions from health care practitioners. Participants who received education did not perform high-quality HBPM. Participants who did not receive education mimicked BP measurement methods of health care practitioners, "I do it the way I've seen them do it."

Conclusions: HBPM is not performed according to guideline recommendations, and adults who received ad hoc education did not perform high-quality HBPM. These findings highlight a need for effective education to support HBPM for clinical decision-making.

背景:根据血压(BP)指南进行家庭血压测量(HBPM)需要对患者进行教育。目前尚不清楚在家中如何测量血压以及提供了哪些教育,这正是本研究的目的所在:在进行 HBPM 的澳大利亚成年人中开展混合方法研究(2023 年 6 月至 12 月)。参与者完成了一项包含 30 个项目的在线调查,内容涉及他们是否遵循指南建议以及他们所接受的 HBPM 教育。为了进一步探究调查主题,对特定样本进行了电话访谈:参与者(n=350)为中年人(58±16 岁;54% 为女性),大多数(n=250,71%)患有高血压。调查参与者并不总是遵循 HBPM 指南建议。大多数参与者都是坐着测量血压(人数=316,90%),袖带安装在裸臂上(人数=269,77%)。只有 15% 的参与者在早晨和傍晚测量血压(人数=54),26% 的参与者在 7 天内平均测量血压读数(人数=90)。访谈参与者(人数=34)描述了在一天中不同时间做不同事情后测量血压的情况。三分之一的参与者(n=112,37%)接受过 HBPM 教育,访谈参与者将其描述为医护人员的模糊口头指导。接受过教育的参与者并未进行高质量的 HBPM。未接受教育的参与者模仿医护人员的血压测量方法,"我看到他们怎么做,我就怎么做":HBPM 并未按照指南建议进行,接受临时教育的成人并未进行高质量的 HBPM。这些发现突出表明,有必要开展有效的教育,为临床决策提供 HBPM 支持。
{"title":"Home Blood Pressure Measurements Are Not Performed According to Guidelines and Standardized Education Is Urgently Needed.","authors":"Eleanor Clapham, Dean S Picone, Samuel Carmichael, George S Stergiou, Norm R C Campbell, John Stevens, Carol Batt, Aletta E Schutte, Niamh Chapman","doi":"10.1161/HYPERTENSIONAHA.124.23678","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23678","url":null,"abstract":"<p><strong>Background: </strong>Patient education is needed to perform home blood pressure measurement (HBPM) according to blood pressure (BP) guidelines. It is not known how BP is measured at home and what education is provided, which was the aim of the study.</p><p><strong>Methods: </strong>Mixed-methods study among Australian adults who perform HBPM (June to December 2023). Participants completed a 30-item online survey on whether they followed guideline recommendations and the education they received for HBPM. Phone interviews were conducted among a purposive sample to further explore survey topics.</p><p><strong>Results: </strong>Participants (n=350) were middle-aged (58±16 years; 54% women), and most (n=250, 71%) had hypertension. Guideline recommendations for HBPM were not always followed by survey participants. Most participants measured BP seated (n=316, 90%) with the cuff fitted to a bare arm (n=269, 77%). Only 15% measured BP in the morning and evening (n=54) and 26% averaged the BP readings over 7 days (n=90). Interview participants (n=34) described measuring BP at \"different times of the day after doing different things.\" One-third of participants (n=112, 37%) received education for HBPM, which interview participants described as vague verbal instructions from health care practitioners. Participants who received education did not perform high-quality HBPM. Participants who did not receive education mimicked BP measurement methods of health care practitioners, \"I do it the way I've seen them do it.\"</p><p><strong>Conclusions: </strong>HBPM is not performed according to guideline recommendations, and adults who received ad hoc education did not perform high-quality HBPM. These findings highlight a need for effective education to support HBPM for clinical decision-making.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"149-159"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension. 吡哆斯的明治疗直立性低血压的临床疗效分析。
IF 8.3 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-27 DOI: 10.1161/hypertensionaha.124.24050
Luis E Okamoto,Emily Walsh,Andre Diedrich,Cyndya A Shibao,Alfredo Gamboa,Bonnie K Black,Sachin Paranjape,James A S Muldowney,Ralf Habermann,Amanda Peltier,Kishan Tarpara,Italo Biaggioni
BACKGROUNDThe cholinesterase inhibitor pyridostigmine is used to treat orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia, thereby harnessing residual sympathetic tone to increase blood pressure (BP) preferentially in the upright posture. We hypothesized that less severe autonomic impairment was associated with greater pressor responses to pyridostigmine.METHODSTo identify predictors of pressor response, linear regression analyses between the effect of pyridostigmine on upright BP and markers of autonomic impairment were retrospectively conducted on 38 patients who had a medication trial with pyridostigmine (60 mg single dose).RESULTSPyridostigmine increased upright BP by 4±2/3±2 mm Hg but with a wide range of responses (-20/-15 to 29/27 mm Hg; interquartile range, -6/-4 to 11/8 mm Hg). No differences were found between multiple system atrophy (n=14) and patients with pure autonomic failure (n=24). The upright BP response to pyridostigmine was negatively correlated with supine BP and with the pressure recovery time of the Valsalva maneuver, an index of severity of autonomic impairment. In patients with multiple system atrophy, the systolic blood pressure pressor response to pyridostigmine was also positively correlated with the increase in upright heart rate divided by the fall in systolic blood pressure (∆ heart rate/∆ systolic blood pressure) and with upright plasma norepinephrine, both surrogates of residual autonomic function.CONCLUSIONSPatients with less severe autonomic impairment are more likely to have a positive pressor response to pyridostigmine. Importantly, in this cohort of patients with severe autonomic failure, pyridostigmine was not effective in those with supine hypertension who would benefit the most from the preferential pressor effect of the drug on upright BP.REGISTRATIONURL: http://www.clinicaltrials.gov; Unique identifier: NCT00223691.
胆碱酯酶抑制剂吡哆斯的明通过促进自主神经节的胆碱能神经传递,从而利用残留的交感神经张力优先提高直立姿势的血压,用于治疗直立性低血压。我们假设不太严重的自主神经损伤与吡哆斯的明产生的更大的压力反应有关。方法回顾性分析38例接受吡哆斯的明(单次剂量60 mg)治疗的患者,对吡哆斯的明对直立血压的影响与自主神经损伤标志物之间的线性回归分析,以确定降压反应的预测因素。结果吡多斯的明使直立血压升高4±2/3±2 mm Hg,但作用范围广(-20/-15 ~ 29/27 mm Hg;四分位数范围,-6/-4至11/8毫米汞柱)。多系统萎缩(n=14)和单纯自主神经衰竭(n=24)患者之间无差异。吡哆斯的明对直立血压的反应与仰卧血压和自主神经损伤严重程度指标Valsalva动作的压力恢复时间呈负相关。在多系统萎缩患者中,吡地斯的明对收缩压的影响也与直立心率的增加除以收缩压的下降(∆心率/∆收缩压)和直立血浆去甲肾上腺素呈正相关,两者都是残余自主神经功能的替代品。结论自主神经损伤程度较轻的患者更可能对吡哆斯的明产生积极的降压反应。重要的是,在这组严重自主神经衰竭的患者中,吡啶多斯的明对仰卧位高血压患者无效,而仰卧位高血压患者将从该药对直立血压的优先降压作用中获益最多。REGISTRATIONURL: http://www.clinicaltrials.gov;唯一标识符:NCT00223691。
{"title":"Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.","authors":"Luis E Okamoto,Emily Walsh,Andre Diedrich,Cyndya A Shibao,Alfredo Gamboa,Bonnie K Black,Sachin Paranjape,James A S Muldowney,Ralf Habermann,Amanda Peltier,Kishan Tarpara,Italo Biaggioni","doi":"10.1161/hypertensionaha.124.24050","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24050","url":null,"abstract":"BACKGROUNDThe cholinesterase inhibitor pyridostigmine is used to treat orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia, thereby harnessing residual sympathetic tone to increase blood pressure (BP) preferentially in the upright posture. We hypothesized that less severe autonomic impairment was associated with greater pressor responses to pyridostigmine.METHODSTo identify predictors of pressor response, linear regression analyses between the effect of pyridostigmine on upright BP and markers of autonomic impairment were retrospectively conducted on 38 patients who had a medication trial with pyridostigmine (60 mg single dose).RESULTSPyridostigmine increased upright BP by 4±2/3±2 mm Hg but with a wide range of responses (-20/-15 to 29/27 mm Hg; interquartile range, -6/-4 to 11/8 mm Hg). No differences were found between multiple system atrophy (n=14) and patients with pure autonomic failure (n=24). The upright BP response to pyridostigmine was negatively correlated with supine BP and with the pressure recovery time of the Valsalva maneuver, an index of severity of autonomic impairment. In patients with multiple system atrophy, the systolic blood pressure pressor response to pyridostigmine was also positively correlated with the increase in upright heart rate divided by the fall in systolic blood pressure (∆ heart rate/∆ systolic blood pressure) and with upright plasma norepinephrine, both surrogates of residual autonomic function.CONCLUSIONSPatients with less severe autonomic impairment are more likely to have a positive pressor response to pyridostigmine. Importantly, in this cohort of patients with severe autonomic failure, pyridostigmine was not effective in those with supine hypertension who would benefit the most from the preferential pressor effect of the drug on upright BP.REGISTRATIONURL: http://www.clinicaltrials.gov; Unique identifier: NCT00223691.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"14 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic Variants Associated With Preeclampsia and Maternal Serum sFLT1 Levels. 遗传变异与子痫前期和母体血清sFLT1水平相关。
IF 8.3 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-26 DOI: 10.1161/hypertensionaha.124.23400
Jasmine A Mack,Ulla Sovio,Felix R Day,Francesca Gaccioli,Emma Cook,Nadua Bayzid,Marius Cotic,Nathan Dunton,Gaganjit Madhan,Alison Motsinger-Reif,John R B Perry,D Stephen Charnock-Jones,Gordon C S Smith
BACKGROUNDElevated maternal serum sFLT1 (soluble fms-like tyrosine kinase 1) has a key role in the pathophysiology of preeclampsia. We sought to determine the relationship between the maternal and fetal genome and maternal levels of sFLT1 at 12, 20, 28, and 36 weeks of gestational age (wkGA).METHODSWe studied a prospective cohort of nulliparous women (3968 mother-child pairs). We related maternal and fetal genotype to the adjusted sFLT1 Z score and sFLT1:placental growth factor (PlGF) ratio Z score at each wkGA and the change in the Z score between 28 and 36 wkGA (Δ36-28). We studied genetic variants from a previous fetal genome-wide association study of preeclampsia and an externally defined polygenic score from a maternal genome-wide association study of preeclampsia.RESULTSFour variants from the fetal preeclampsia genome-wide association study were positively associated with sFLT1 and sFLT1:PlGF Z score at 36 wkGA, and FLT1 enhancer single-nucleotide polymorphisms were associated with increased Δ36-28 of sFLT1. The associations were specific for the fetal genome or stronger for the fetal than the maternal genome. An increased risk of preeclampsia based on the maternal polygenic score for preeclampsia was associated with lower levels of sFLT1 and sFLT1:PlGF ratio in the first trimester and a greater Δ36-28 for sFLT1.CONCLUSIONSThe current data are consistent with a causal association between sFLT1 released by the placenta in late pregnancy and the pathophysiology of preeclampsia. The data are also consistent with maternal components to the protective effect of high sFLT1 in the first trimester and the rise in third-trimester sFLT1 levels and preeclampsia.
背景:升高的母体血清sFLT1(可溶性膜样酪氨酸激酶1)在子痫前期的病理生理中起关键作用。我们试图确定母体和胎儿基因组与母体在12、20、28和36周胎龄(wkGA)时sFLT1水平之间的关系。方法我们研究了一组未生育妇女(3968对母子)的前瞻性队列。我们将母体和胎儿的基因型与调整后的sFLT1 Z评分、sFLT1:胎盘生长因子(PlGF)比值Z评分以及28 - 36个wkGA之间Z评分的变化联系起来(Δ36-28)。我们研究了先前子痫前期胎儿全基因组关联研究中的遗传变异和子痫前期母体全基因组关联研究中外部定义的多基因评分。结果来自胎儿子痫前期全基因组关联研究的4个变异与sFLT1和sFLT1呈正相关:PlGF Z评分在36 wkGA时,FLT1增强子单核苷酸多态性与sFLT1 Δ36-28升高相关。这种关联是胎儿基因组特有的,或者胎儿比母体基因组更强。基于母体子痫前期多基因评分的子痫前期风险增加与妊娠早期较低水平的sFLT1和sFLT1:PlGF比值以及较高的sFLT1 Δ36-28相关。结论目前的数据与妊娠晚期胎盘释放的sFLT1与子痫前期病理生理之间的因果关系一致。这些数据也与妊娠早期高sFLT1的保护作用以及妊娠晚期sFLT1水平升高和先兆子痫的母体成分一致。
{"title":"Genetic Variants Associated With Preeclampsia and Maternal Serum sFLT1 Levels.","authors":"Jasmine A Mack,Ulla Sovio,Felix R Day,Francesca Gaccioli,Emma Cook,Nadua Bayzid,Marius Cotic,Nathan Dunton,Gaganjit Madhan,Alison Motsinger-Reif,John R B Perry,D Stephen Charnock-Jones,Gordon C S Smith","doi":"10.1161/hypertensionaha.124.23400","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.23400","url":null,"abstract":"BACKGROUNDElevated maternal serum sFLT1 (soluble fms-like tyrosine kinase 1) has a key role in the pathophysiology of preeclampsia. We sought to determine the relationship between the maternal and fetal genome and maternal levels of sFLT1 at 12, 20, 28, and 36 weeks of gestational age (wkGA).METHODSWe studied a prospective cohort of nulliparous women (3968 mother-child pairs). We related maternal and fetal genotype to the adjusted sFLT1 Z score and sFLT1:placental growth factor (PlGF) ratio Z score at each wkGA and the change in the Z score between 28 and 36 wkGA (Δ36-28). We studied genetic variants from a previous fetal genome-wide association study of preeclampsia and an externally defined polygenic score from a maternal genome-wide association study of preeclampsia.RESULTSFour variants from the fetal preeclampsia genome-wide association study were positively associated with sFLT1 and sFLT1:PlGF Z score at 36 wkGA, and FLT1 enhancer single-nucleotide polymorphisms were associated with increased Δ36-28 of sFLT1. The associations were specific for the fetal genome or stronger for the fetal than the maternal genome. An increased risk of preeclampsia based on the maternal polygenic score for preeclampsia was associated with lower levels of sFLT1 and sFLT1:PlGF ratio in the first trimester and a greater Δ36-28 for sFLT1.CONCLUSIONSThe current data are consistent with a causal association between sFLT1 released by the placenta in late pregnancy and the pathophysiology of preeclampsia. The data are also consistent with maternal components to the protective effect of high sFLT1 in the first trimester and the rise in third-trimester sFLT1 levels and preeclampsia.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"54 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced AT2R Signaling Contributes to Endothelial Dysfunction After Preeclampsia. 降低AT2R信号有助于子痫前期内皮功能障碍。
IF 8.3 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-12-26 DOI: 10.1161/hypertensionaha.124.24098
Kelsey S Schwartz,Mingyao Sun,Diana I Jalal,Mark K Santillan,Anna E Stanhewicz
BACKGROUNDWomen who had preeclampsia (a history of preeclampsia) have a >4-fold risk of developing cardiovascular disease compared with women who had an uncomplicated pregnancy (history of healthy pregnancy). Despite the remission of clinical symptoms after pregnancy, vascular endothelial dysfunction persists postpartum, mediated in part by exaggerated Ang II (angiotensin II)-mediated constriction. However, the role of vasodilatory AT2Rs (Ang II type 2 receptors) in this dysfunction is unknown. We examined the functional role of AT2R in the microvasculature postpartum and whether acute activation of AT2R improves microvascular endothelial function after preeclampsia.METHODSOverall, 24 women (n=12/group) participated. We measured cutaneous vascular conductance responses to (1) graded infusion of compound 21 (AT2R agonist; 10-14-10-8M) alone or with NG-nitro-l-arginine methyl ester (NO synthase inhibitor; 15 mM) and (2) a standardized local heating protocol in control and 10-11M compound 21-treated sites. Expression of Ang II receptor subtypes I and II in biopsied venous endothelial cells was quantified using immunofluorescence.RESULTSAT2R-mediated dilation (P<0.01) and the NO-dependent contribution (P=0.003) of this response were reduced in women with a history of preeclampsia. Endothelial AT2R expression was lower in women with a history of preeclampsia (P<0.01), but there were no differences in endothelial AT1R (Ang II type 1 receptor) expression (P>0.05). Acute activation of AT2R during local heating improved endothelium (P<0.01) and NO-dependent (P<0.01) dilation in women with a history of preeclampsia but had no effect in women with a history of healthy pregnancy (both P>0.05).CONCLUSIONSReductions in AT2R-mediated dilation contribute to attenuated or impaired endothelial function in women who had a pregnancy complicated by preeclampsia. Furthermore, AT2R activation may improve endothelial function through NO-dependent mechanisms in otherwise healthy women who had preeclampsia before the onset of cardiovascular disease.REGISTRATIONURL: https://www.clinicaltrials.gov; Unique identifier: NCT05937841.
背景:有子痫前期(有子痫前期病史)的妇女患心血管疾病的风险是无并发症妊娠(健康妊娠史)妇女的4倍。尽管妊娠后临床症状缓解,但产后血管内皮功能障碍持续存在,部分是由angii(血管紧张素II)介导的过度收缩介导的。然而,血管舒张AT2Rs (Ang II型2受体)在这种功能障碍中的作用尚不清楚。我们研究了AT2R在产后微血管中的功能作用,以及AT2R的急性激活是否能改善子痫前期微血管内皮功能。方法共24名女性(n=12/组)参与。我们测量了皮下血管传导对以下情况的反应:(1)分级输注化合物21 (AT2R激动剂;10-14-10-8M)单独或与ng -硝基-l-精氨酸甲酯(NO合成酶抑制剂;15 mM)和(2)控制和10-11M化合物21处理场地的标准化局部加热方案。应用免疫荧光法定量检测活组织静脉内皮细胞中Ang II受体亚型I和II的表达。结果sat2r介导的舒张(P0.05)。局部加热时AT2R的急性激活改善了内皮细胞(P0.05)。结论:at2r介导的舒张降低有助于妊娠合并子痫前期妇女内皮功能减弱或受损。此外,AT2R激活可能通过no依赖机制改善心血管疾病发病前患有子痫前期的健康女性的内皮功能。REGISTRATIONURL: https://www.clinicaltrials.gov;唯一标识符:NCT05937841。
{"title":"Reduced AT2R Signaling Contributes to Endothelial Dysfunction After Preeclampsia.","authors":"Kelsey S Schwartz,Mingyao Sun,Diana I Jalal,Mark K Santillan,Anna E Stanhewicz","doi":"10.1161/hypertensionaha.124.24098","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24098","url":null,"abstract":"BACKGROUNDWomen who had preeclampsia (a history of preeclampsia) have a >4-fold risk of developing cardiovascular disease compared with women who had an uncomplicated pregnancy (history of healthy pregnancy). Despite the remission of clinical symptoms after pregnancy, vascular endothelial dysfunction persists postpartum, mediated in part by exaggerated Ang II (angiotensin II)-mediated constriction. However, the role of vasodilatory AT2Rs (Ang II type 2 receptors) in this dysfunction is unknown. We examined the functional role of AT2R in the microvasculature postpartum and whether acute activation of AT2R improves microvascular endothelial function after preeclampsia.METHODSOverall, 24 women (n=12/group) participated. We measured cutaneous vascular conductance responses to (1) graded infusion of compound 21 (AT2R agonist; 10-14-10-8M) alone or with NG-nitro-l-arginine methyl ester (NO synthase inhibitor; 15 mM) and (2) a standardized local heating protocol in control and 10-11M compound 21-treated sites. Expression of Ang II receptor subtypes I and II in biopsied venous endothelial cells was quantified using immunofluorescence.RESULTSAT2R-mediated dilation (P<0.01) and the NO-dependent contribution (P=0.003) of this response were reduced in women with a history of preeclampsia. Endothelial AT2R expression was lower in women with a history of preeclampsia (P<0.01), but there were no differences in endothelial AT1R (Ang II type 1 receptor) expression (P>0.05). Acute activation of AT2R during local heating improved endothelium (P<0.01) and NO-dependent (P<0.01) dilation in women with a history of preeclampsia but had no effect in women with a history of healthy pregnancy (both P>0.05).CONCLUSIONSReductions in AT2R-mediated dilation contribute to attenuated or impaired endothelial function in women who had a pregnancy complicated by preeclampsia. Furthermore, AT2R activation may improve endothelial function through NO-dependent mechanisms in otherwise healthy women who had preeclampsia before the onset of cardiovascular disease.REGISTRATIONURL: https://www.clinicaltrials.gov; Unique identifier: NCT05937841.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"202 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1